Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged bleeding due to the lack of factors required for the clotting of blood.
According to World Federation of Hemophilia, about one in 10,000 people are born with this disease. Various types of drugs are injected into the veins of patient in order to replace the clotting factors, which are missing or low in number.
Browse the report: www.orbisresearch.com/reports/inde…tion-outlook-2022
As per RNCOS report “Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate, Feiba), By Type of Hemophilia, By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement, Immune Tolerance Induction) Outlook 2022”, the global hemophilia therapeutics market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global hemophilia therapeutics market.
The report provides insight about the major drivers, such as increasing awareness about hemophilia and its treatment options, grants and tax credits, for the global hemophilia therapeutics market. Furthermore, few challenges, such as manufacturing difficulties and low switching rate between hemophilia medicines, which are hindering the growth of the global hemophilia therapeutics market have also been mentioned in the report.
In addition, the report also highlights various opportunities available for growth of the global hemophilia therapeutics market.
The global hemophilia therapeutics market has been segmented on the basis of type of hemophilia, i.e. Hemophilia A, Hemophilia B, and Others.
Hemophilia A occupies the largest share in the global hemophilia therapeutics market, owing to the highest prevalence of this type of hemophilia. Moreover, strong pipeline of drugs for Hemophilia A is also helping its market to grow all across the globe.
Request a sample of the report: www.orbisresearch.com/contacts/request-sample/333582
Furthermore, the global hemophilia therapeutics market has also been segmented on the basis of type of treatment. According to the report, the treatment for hemophilia can either be an on-demand treatment or a prophylaxis treatment.
Currently, on-demand treatment dominates the global hemophilia therapeutics market, as patients usually go for treatment only when bleeding episodes occur. However, prophylaxis is forecasted to be the fastest growing segment owing to the requirement of better management of bleeding episodes.
Similarly, the market has also been segmented on the basis of type of therapy into replacement therapy and immune tolerance induction therapy. Apart from these types of therapies, efforts are also being made by various pharmaceutical and biotech companies to develop gene therapy for the treatment of hemophilia.
Gene therapy is an evolving field which focuses on correcting defective genes in order to cure genetic diseases, such as hemophilia. Use of gene therapy for hemophilia treatment is a promising option, as hemophilia is caused due to a single genetic defect.
Even a minimal success from this procedure can mean significant improvement in quality of life for patients. Numerous companies, such as BioMarin Pharmaceuticals and uniQure, are carrying out clinical trials for gene therapies for the treatment of hemophilia.
Hence, gene therapy presents great opportunities for the growth of global hemophilia therapeutics market in the coming years.
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global hemophilia therapeutics market.
Moreover, the report also highlights various mergers and acquisitions taking place in the global hemophilia therapeutics industry. The pipeline of hemophilia drugs have also been mentioned in the report.
The last section of the report discusses about the prominent players in global hemophilia therapeutics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline.
The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hemophilia therapeutics market.
Major Points From The Table Of Contents:
Hemophilia: An Overview
Global Hemophilia Therapeutics Market Outlook 2022
Major Products in Hemophilia Therapeutics Market
Market Segmentation by Type of Hemophilia
Market Segmentation by Type of Treatment
Market Segmentation by Type of Therapy
Market Segmentation by Geography
Gene Therapy – Future of Hemophilia Treatment
Trends & Developments
Mergers & Acquisitions
Category: Market Research Publishers and RetailersCompany about: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...